Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
Wayne State University Department of Oncology/Karmanos Cancer Institute, Detroit, MI, USA.
Transl Behav Med. 2023 Apr 15;13(4):255-267. doi: 10.1093/tbm/ibac099.
Shared decision-making (SDM) is a key component of patient-centered healthcare. SDM is particularly pertinent in the relapsed and/or refractory multiple myeloma (RRMM) setting, in which numerous treatment options can present challenges for identifying optimal care. However, few studies have assessed the extent and relevance of SDM and patient-centered communication (PCC) in RRMM. To describe treatment decision-making patterns between physicians and patients in the RRMM setting, we conducted online surveys of patients and physicians in the USA to compare their perspectives on the process of treatment decision-making. We analyzed the surveys descriptively. Two hundred hematologists/oncologists and 200 patients with RRMM receiving second-line (n = 89), third-line (n = 65), and fourth-line (n = 46) therapy participated. Top treatment goals for physicians and patients included extending overall survival (among 76% and 83% of physicians and patients, respectively) and progression-free survival (among 54% and 77% of physicians and patients, respectively), regardless of the number of prior relapses. Thirty percent of physicians believed patients preferred a shared approach to treatment decision-making, while 40% of patients reported most often preferring a shared role in treatment decision-making. One-fourth of patients most often preferred physicians to make the final treatment decision after seriously considering their opinion. Thirty-two percent of physicians and 16% of patients recalled ≥3 treatment options presented at first relapse. Efficacy was a primary treatment goal for patients and physicians. Discrepancies in their perceptions during RRMM treatment decision-making exist, indicating that communication tools are needed to facilitate SDM and PCC.
共同决策(SDM)是以患者为中心的医疗保健的关键组成部分。SDM 在复发性和/或难治性多发性骨髓瘤(RRMM)环境中尤为重要,因为有许多治疗选择可能会对确定最佳治疗方法带来挑战。然而,很少有研究评估 SDM 和以患者为中心的沟通(PCC)在 RRMM 中的程度和相关性。为了描述 RRMM 环境中医生和患者之间的治疗决策模式,我们对美国的患者和医生进行了在线调查,以比较他们对治疗决策过程的看法。我们对调查进行了描述性分析。共有 200 名血液科/肿瘤科医生和 200 名 RRMM 患者参与了二线(n=89)、三线(n=65)和四线(n=46)治疗的调查。医生和患者的主要治疗目标包括延长总生存期(分别有 76%和 83%的医生和患者)和无进展生存期(分别有 54%和 77%的医生和患者),无论复发次数如何。30%的医生认为患者更喜欢共同决策的治疗方法,而 40%的患者报告他们通常更喜欢在治疗决策中共同发挥作用。四分之一的患者通常最希望在认真考虑他们的意见后由医生做出最终治疗决定。32%的医生和 16%的患者回忆起第一次复发时提出了≥3 种治疗方案。疗效是患者和医生的主要治疗目标。在 RRMM 治疗决策过程中存在他们看法的差异,这表明需要沟通工具来促进 SDM 和 PCC。